Odyssey’s CEO sees $304M IPO as chance to create a ‘little large pharma’

AI Summary

Odyssey Therapeutics has launched an initial public offering (IPO) worth $304 million, aiming to establish itself as a significant player in the pharmaceutical sector. The move represents the growing trend of biotech firms seeking funding through public markets.

Odyssey Therapeutics has become the latest biotech to voyage to the public markets via an upsized $304 million IPO this morning.